Antithrombotic therapy is the cornerstone of the management of patients with acute coronary syndrome (ACS), which result in lower risk of mortality and ischemic events. But, accompanied side effect of bleeding always causing worsens outcomes. Tools to evaluate risk/benefit ratio is useful in daily practice. The in-used scores, such as CRUSADE, are derived from retrospective studies, without all types of ACS and without long-term prediction. This project aims to establish a database of anti-thrombosis treatment and bleeding in five large centers in Beijing through the observational registry of ACS. With the database, establish a bleeding risk assessment system that can be used for all ACS patients and can predict the full course of antithrombotic treatment.
Study Type
OBSERVATIONAL
Enrollment
6,379
Beijing Anzhen Hospital
Beijing, China
The number of event of bleeding
The number of event of bleeding (BARC 2 to 5) within 30 days after enrollment
Time frame: 30 days
The number of event of bleeding
The number of event of bleeding (BARC 2 to 5) within 1 year after enrollment
Time frame: 1 year
The number of event of bleeding
The number of event of bleeding (BARC 1 to 5) within 30 days and 1year after enrollment
Time frame: 30 days and 1 year
number of event of major adverse cardiovascular or cerebrovascular events
number of event of major adverse cardiovascular or cerebrovascular events within 30 days and 1year after enrollment
Time frame: 30 days and 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.